¼ÒÈ­±â°ú °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾à(2016-2025³â)
Gastrointestinal Collaboration and Licensing Deals 2016-2025
»óǰÄÚµå : 1708051
¸®¼­Ä¡»ç : Current Partnering, a brand of Biopharma Research Ltd.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,995 £Ü 5,580,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,995 £Ü 8,374,000
PDF (Multi User License - 2 to 5 Users) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2-5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,995 £Ü 11,168,000
PDF (Company Wide License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¾÷°è¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, 2016-2025³â ¼ÒÈ­±â°ú °øµ¿ ¿¬±¸¡¤¶óÀ̼±½Ì °è¾à 398°Ç¿¡ °üÇÑ °è¾à Á¶°Ç µîÀÇ »ó¼¼ µ¥ÀÌÅ͸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

°³¿ä

Á¦1Àå ¼­·Ð

Á¦2Àå ¼ÒÈ­±â°ú °è¾àÀÇ µ¿Çâ

Á¦3Àå ¼ÒÈ­±â°ú ÆÄÆ®³Ê °è¾à¿¡ °üÇÑ À繫Àû °è¾à Á¶°Ç

Á¦4Àå ¼ÒÈ­±â°úÀÇ ÁÖ¿ä °è¾à°ú ±³¼·ÀÚ

Á¦5Àå ¼ÒÈ­±â°ú °è¾à ¹®¼­ µð·ºÅ丮

Á¦6Àå ¼ÒÈ­±â°ú °è¾à : Ä¡·á Ç¥Àûº°

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Gastrointestinal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gastrointestinal deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 398 gastrointestinal deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gastrointestinal dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gastrointestinal dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the gastrointestinal field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in gastrointestinal dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of gastrointestinal deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of gastrointestinal deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in gastrointestinal deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gastrointestinal Collaboration and Licensing Deals provides the reader with the following key benefits:

Report scope

Gastrointestinal Collaboration and Licensing Deals includes:

In Gastrointestinal Collaboration and Licensing Deals, the available deals are listed by:

Analyzing contract agreements allows due diligence of:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gastrointestinal dealmaking

Chapter 3 - Financial deal terms for gastrointestinal partnering

Chapter 4 - Leading gastrointestinal deals and dealmakers

Chapter 5 - Gastrointestinal contract document directory

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

Table of figures

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â